What records are connected here?
- Evidence lanes
- 2
- Source years
- 3
- Drugs@FDA applications
- 0
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
In clinical trials1,2,3Evidence: Smaller human trialsBrain, nerves and sleep
Also called ARA 2901
Cibinetide, also called ARA 290, is a synthetic 11-amino-acid peptide recorded in FDA’s substance registry.1 In a randomized, placebo-controlled Phase 2b trial of 64 people with sarcoidosis-related small nerve fiber loss and nerve pain, one of three strengths increased corneal nerve fiber area after 28 days.2 No FDA approval is reported in the sources reviewed here. Cibinetide does not appear on FDA’s compounding safety-risk page and is not among the six peptides in HHS’s October 2026 draft policy.1,3,5
| What it is | A synthetic 11-amino-acid peptide (pGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser), recorded as cibinetide, ARA 290 and pHBSP in FDA’s substance registry.1 |
|---|---|
| FDA status | No FDA approval is reported in the sources reviewed here. FDA’s compounding safety-risk page, current as of April 22, 2026, does not list cibinetide.1,3 |
| Human evidence | Small randomized, placebo-controlled trials, including a 28-day Phase 2b trial in 64 people with sarcoidosis-related nerve damage.2 |
| Evidence strength | Smaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned |
Cibinetide is a synthetic peptide of 11 amino acids. FDA’s substance registry records it as cibinetide, ARA 290, ARA-290 and pHBSP.1
The 2017 trial authors describe cibinetide as an agonist of the innate repair receptor and studied whether it could reverse the loss of small nerve fibers.2
In the 2017 Phase 2b trial, 64 people with sarcoidosis-associated small nerve fiber loss and neuropathic pain were randomized to one of three strengths of cibinetide or placebo for 28 days.2
The main outcome, change in corneal nerve fiber area, improved significantly only with the middle strength. Pain improved significantly in all groups; among those with moderate to severe pain, the placebo-corrected reduction with the middle strength was not statistically significant.2
Evidence-strength label: Smaller controlled human trials. How this label is assigned
None of the sources reviewed here reports an approval of cibinetide by FDA.1,3
FDA’s compounding safety-risk page, current as of April 22, 2026, does not list cibinetide.3
HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Cibinetide is not among them.4,5
Whether the nerve fiber changes seen over 28 days lead to lasting relief of pain or better function, which the trial was too short and small to show.2
PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.
Go deeper
Everything PeptideScanner has collected for Cibinetide: reviews, official-source readings, registry and literature records, and every change to this profile.
What the trial and literature lists cover. The trials and papers listed for Cibinetide are a bounded selection, not every registration or paper about Cibinetide. For the years before Cibinetide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Cibinetide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Cibinetide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.
Evidence summary
Not FDA-approved; studied in clinical trials. A randomized, placebo-controlled trial of 64 people found more corneal nerve fibers with one strength after 28 days. Cibinetide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
Status sources checked through November 14, 2026. See status sources and coverage →
Explore this profile’s cited source records →
An editorial human-evidence summary has not yet been published.
Living status brief
Not FDA-approved; studied in clinical trials. A randomized, placebo-controlled trial of 64 people found more corneal nerve fibers with one strength after 28 days. Cibinetide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗↗
The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.
These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.
Literature metadata · source date September 28, 2020
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.↗Added to PeptideScanner November 16, 2026Literature metadata · added November 16, 2026
A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.↗Source date September 28, 2020Literature metadata · added November 16, 2026
ARA 290 for treatment of small fiber neuropathy in sarcoidosis.↗Source date May 25, 2018Literature metadata · added November 16, 2026
ARA 290 relieves pathophysiological pain by targeting TRPV1 channel: Integration between immune system and nociception.↗Source date May 25, 2018PeptideScanner currently has no selected regulatory records and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.
PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.
Evidence Map v1
This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.
1 of 1 selected trial records include at least one phase value; 1 of 1 include a status value in the retained structured contract.
3 of 3 selected PubMed records include attributed title, venue, publication date, and publication-type fields.
Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.
Research hub
PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.
PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide.
PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
PubMed lists PMID 26774587 in Peptides as Journal Article, with publication-date metadata of 2016-01-13 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.
3 with attributed title, venue, publication-date, and type metadata.
0 public history versions across these dated registry records; status labels apply only to each cited observation.
Selected records span April 18, 2017 to September 28, 2020. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.
These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.
Literature metadata
PubMed lists PMID 32674280 in Journal of clinical medicine as Journal Article, with publication-date metadata of 2020-07-14 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 24555851 in Expert opinion on investigational drugs as Journal Article, Review, with publication-date metadata of 2014-02-21 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Literature metadata
PubMed lists PMID 26774587 in Peptides as Journal Article, with publication-date metadata of 2016-01-13 (day precision). PeptideScanner associated the retained record with the identity slug cibinetide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02039687 at 2026-11-16T01:46:13.488Z. Its registry update date was 2017-04-18, and PeptideScanner's reviewed identity mapping was cibinetide.↗
Citations
Numbered markers in the text point here. Each link opens the original public record.
FDA Global Substance Registration System · Official source · Source checked November 15, 2026
Investigative Ophthalmology & Visual Science · Official source · Source checked November 15, 2026
U.S. Food and Drug Administration · Official source · Source checked November 14, 2026
Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026
U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026